Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer

INTRODUCTION: Erlotinib and gefitinib are the most commonly used epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of EGFR mutant nonsmall cell lung cancer (NSCLC). Both erlotinib and gefitinib have shown equal efficacy in terms of response rates and overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Udupa, Karthik S, Rajendranath, Rejiv, Sagar, Tenali, Thomas, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398099/
https://www.ncbi.nlm.nih.gov/pubmed/28469331
http://dx.doi.org/10.4103/0971-5851.203502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398099/
https://www.ncbi.nlm.nih.gov/pubmed/28469331
http://dx.doi.org/10.4103/0971-5851.203502

Ejemplares similares